Effects of Continuous Veno-venous Haemofiltration on Plasma Lactate in Critically Ill Patients

Kidney Injury, Acute Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01824771
• Other study ID #: 2013232
• Status: Completed
• Start date: March 3, 2013
• Est. completion date: March 20, 2015

Study information

• Verified date: July 2022
• Source: First Affiliated Hospital, Sun Yat-Sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Continuous Veno-Venous Hemofiltration (CVVH) can eliminate metabolic products effectively and replace renal function partly. It is widely used in intensive care units (ICUs), especially for patients with acute kidney injury/failure in an unstable hemodynamic status. Lactate is a molecule smaller than glucose, which can pass through filtration membrane freely in CVVH. Therefore, the blood lactate concentrations would no longer reflect tissue oxygenation status in patients with unstable hemodynamic status. However, there is no prospective study evaluated the effect of CVVH on lactate removal in critically ill patients. The influence of different dose of CVVH on lactate elimination is not clear in patients with different level of serum lactate. Our study aimed to find out how the dose of CVVH effects on lactate clearance, and then re-estimate the prognostic value of lactate in critically ill patients with CVVH.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: March 20, 2015
• Est. primary completion date: March 3, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. The critical ill patients with acute kidney injury

2. Patients requiring continuous veno-venous hemofiltration

3. APACHE II scores more than 12

4. Arterial lactate is higher than 0.5mmol/L but lower than 15mmol/L (due to the sensitivity and optimal measuring range of the equipment)

5. Continuous veno-venous hemofiltration for at least 12 hrs

6. Hemo-filter age of <24 hrs

Exclusion Criteria:

1. APACHE II scores lower than 12

2. patients' age are more than 75Y or lower than 18Y

Related Conditions & MeSH terms

• Acute Kidney Injury
• Kidney Injury, Acute

Intervention

Other:
• Plasma lactate were measured
Three different doses (20 ml/kg/h, 35 ml/kg/h and 45 ml/kg/h) of CVVH were applied to critically ill patients who experiencing CVVH. Each dose of CVVH was sequentially gave to each patient and lasted for 30 minutes separately

Locations

Country	Name	City	State
China	The first affiliated hospital, Sun Yat-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

References & Publications (1)

Levraut J, Ciebiera JP, Jambou P, Ichai C, Labib Y, Grimaud D. Effect of continuous venovenous hemofiltration with dialysis on lactate clearance in critically ill patients. Crit Care Med. 1997 Jan;25(1):58-62. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	plasma lactate	Each dose of CVVH was lasted for 30 minutes separately. Blood samples were draw pre-(A) and post-dialyzer (V) site after each dosage of CVVH was carried out for 30 minutes and then plasma lactates were measured immediately	30 minutes